Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Johnson and Johnson
Boehringer Ingelheim
Teva
McKesson
McKinsey
Queensland Health
Merck
Julphar

Generated: January 23, 2018

DrugPatentWatch Database Preview

VENCLEXTA Drug Profile

« Back to Dashboard

When do Venclexta patents expire, and what generic alternatives are available?

Venclexta is a drug marketed by Abbvie Inc and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and six patent family members in forty countries.

The generic ingredient in VENCLEXTA is venetoclax. One supplier is listed for this compound. Additional details are available on the venetoclax profile page.
Summary for VENCLEXTA
International Patents:106
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 50
Clinical Trials: 5
Patent Applications: 66
Drug Prices:see details
DailyMed Link:VENCLEXTA at DailyMed
Drug patent expirations by year for VENCLEXTA
Pharmacology for VENCLEXTA
Drug ClassBCL-2 Inhibitor
Mechanism of ActionP-Glycoprotein Inhibitors
Physiological EffectIncreased Cellular Death

US Patents and Regulatory Information for VENCLEXTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-002 Apr 11, 2016 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for VENCLEXTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,794 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Subscribe
9,034,875 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Subscribe
9,045,475 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for VENCLEXTA

Supplementary Protection Certificates for VENCLEXTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00021 Denmark ➤ Subscribe PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
0873 Netherlands ➤ Subscribe PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207
2017015 Lithuania ➤ Subscribe PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
2017000031 Germany ➤ Subscribe PRODUCT NAME: VENETOCLAX (VENCLYXTO); REGISTRATION NO/DATE: EU/1/16/1138 20161205
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
QuintilesIMS
Chinese Patent Office
Daiichi Sankyo
Cantor Fitzgerald
McKinsey
Colorcon
Federal Trade Commission
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot